Better Pharmaceuticals is working hard!

Recently, Chengdu Better Pharmaceuticals has entered the administrative approval stage for the listing of two category 4 generic drugs, namely ticagrelor tablets and febuxostat tablets.

Source: official website of the State Food and Drug Administration

Ticagrelor is a new type of oral antiplatelet drug developed by AstraZeneca.

AstraZeneca’s ticagrelor tablets were approved to enter the domestic market in November 2012.

From the perspective of the competitive landscape of manufacturers, the original research manufacturer AstraZeneca still dominates the market, but its market share is declining year by year due to the impact of generic drugs.

At present, more than 30 domestic companies have submitted applications for the listing of ticagrelor tablets under the new registration classification, of which 20 have been approved for production and deemed to have been reviewed.

Source: official website of the State Food and Drug Administration

Febuxostat is a xanthine oxidase (XO) inhibitor developed by Japan's Teijin.

The original research product was approved to enter the domestic market in September 2018.

At present, 16 companies have submitted applications for the listing of febuxostat tablets under the new registration classification, of which 7 have been approved for production and deemed to have been reviewed.

Since 2021, Better Pharmaceuticals (including subsidiaries) has been approved for products

Source: Meinenet MED2.

According to data from Mi Nei.

Source: Meinenet database, official website of the State Drug Administration, etc.

Note: The statistics are as of December 2, if there are any omissions, please correct me!